论文部分内容阅读
目的 :设计对照实验,统计探讨康复新液结合酪酸梭菌肠球菌三联活菌片联合疗法在治疗活动期轻中度溃疡性结肠炎方面的临床疗效。方法:以我院2013年7月~2015年9月接收治疗的230例活动期轻中度溃疡性结肠炎患者为研究对象,设计对照实验,统计分析两组患者临床治疗疗效及结肠镜下治疗前后病变情况评分结果。结果 :两组患者治疗后结肠镜下治疗前后病变情况评分结果均有所改善,但接受康复新液结合酪酸梭菌肠球菌三联活菌片联合疗法治疗的实验组患者结肠镜下评分结果及临床总治疗效率均显著优于对照组患者。结论 :康复新液结合酪酸梭菌肠球菌三联活菌片联合疗法治疗活动期轻中度溃疡性结肠炎的临床疗效显著,具有很好的临床推广价值。
OBJECTIVE: To design a control experiment and investigate the clinical effect of Kangfuxin solution combined with Clostridium butyricum enterococci viable combination therapy in the treatment of mild to moderate ulcerative colitis. Methods: A total of 230 patients with mild-to-moderate ulcerative colitis undergoing active treatment from July 2013 to September 2015 in our hospital were enrolled in the study. The control experiment was designed and the clinical efficacy and the results of colonoscopy were compared between the two groups Before and after the lesion score results. Results: The results of colonoscopy before and after treatment showed that the scores of the lesions were improved in both groups. However, the results of colonoscopy and the clinical results of the patients in the experimental group receiving Kangfuxin combined with Clostridium butyricum enterococci triple active viable combination therapy The total treatment efficiency was significantly better than the control group of patients. Conclusion: Kangfuxin liquid combined with Clostridium butyricum enterococci triple viable combination therapy in the treatment of active mild to moderate ulcerative colitis clinical efficacy is significant, with good clinical value.